Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
A new study suggests that GLP-1 receptor agonists may do more than control blood sugar and aid weight loss. People with knee osteoarthritis who took these drugs had a significantly lower long-term risk of needing total knee replacement surgery. The findings appear in the open-access journal Regional Anesthesia & Pain Medicine. That finding is drawing real attention in orthopedic and metabolic medicine circles.
Osteoarthritis affects more than 300 million people worldwide. No approved medication currently slows or reverses the disease itself. When joint damage becomes severe, surgery often becomes the only remaining option. With obesity rates rising and populations aging, more patients will likely reach that threshold each year.
GLP-1 drugs have already shown promise in reducing knee pain from osteoarthritis. This study goes a step further. It suggests these medications may actually protect the joint over time, likely through anti-inflammatory effects and possible cartilage preservation.
Researchers analyzed anonymized records from the TriNetX Global Research Network. They identified adults with knee osteoarthritis diagnosed between January 2010 and December 2024. The team grouped patients by treatment duration (one or three years) and by drug type. Some took any GLP-1 agent; others took specifically semaglutide or tirzepatide. Investigators then compared each group against similar untreated patients using propensity score matching. This method controlled for age, weight, sex, and other relevant health factors.
Results held consistent at every time point. One year of GLP-1 therapy is linked to a 1.4 percentage point drop in cumulative surgical risk by year three. By year eight, that reduction reached nearly 3 percentage points. Semaglutide and tirzepatide, when used for three or more years, produced the strongest results. That combination corresponded to a nearly 5 percentage point reduction at the eight-year mark.
The numbers carry real-world weight. A 1.44% absolute risk reduction over three years of newer-agent use could mean roughly 14,400 fewer knee replacement surgeries annually in the United States. Fewer surgeries translate directly into fewer complications and lower healthcare costs.
The researchers believe the benefits extend beyond weight loss alone. GLP-1 drugs appear to carry direct anti-inflammatory properties. Preclinical evidence also points to potential cartilage protection. This may explain why the effects persisted even after the team controlled for body weight and metabolic conditions.
The study does have limitations. Researchers did not measure frailty, physical activity, disease severity, or functional capacity. The team also drew data from prescription records rather than confirmed medication use. The authors acknowledge these constraints directly. They describe the results as observational associations, not proof of causation.
Even so, the implications are significant. GLP-1 receptor agonists could become a meaningful non-surgical option for managing knee osteoarthritis, especially in patients with type 2 diabetes or metabolic disease. Prospective clinical trials still need to confirm these findings. If they do, treatment guidelines for joint preservation may shift considerably.
